Optimization of globomycin analogs as novel gram-negative antibiotics.
Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Pharmaron Beijing Co., Ltd, No. 6 Taihe Road, BDA, Beijing 100176, PR China.
Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: [email protected]
- Published Article
Bioorganic & medicinal chemistry letters
- Publication Date
Aug 05, 2020
Discovery of novel classes of Gram-negative antibiotics with activity against multi-drug resistant infections is a critical unmet need. As an essential member of the lipoprotein biosynthetic pathway, lipoprotein signal peptidase II (LspA) is an attractive target for antibacterial drug discovery, with the natural product inhibitor globomycin offering a modestly-active starting point. Informed by structure-based design, the globomycin depsipeptide was optimized to improve activity against E. coli. Backbone modifications, together with adjustment of physicochemical properties, afforded potent compounds with good in vivo pharmacokinetic profiles. Optimized compounds such as 51 (E. coli MIC 3.1 μM) and 61 (E. coli MIC 0.78 μM) demonstrate broad spectrum activity against gram-negative pathogens and may provide opportunities for future antibiotic discovery. Copyright © 2020 Elsevier Ltd. All rights reserved.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 09/02/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/32768648